No reductions seen in 28-day mortality or duration of hospital stay in COVID-19 with lopinavir-ritonavir

If enough people in the U.S. pass on vaccine, the nation may not be able to achieve herd immunity

No clinical benefit seen versus placebo for hospital-based health care workers exposed to patients with COVID-19

Higher case fatality rates found to be independent of demographic factors, such as age, sex, and race

Agency says it is especially true in enclosed spaces with inadequate ventilation

MIS-A related to SARS-CoV-2 infection resembles MIS in children; respiratory symptoms often minimal

Fifty percent of phase 3 clinical trials and 100 percent of vaccine trials at risk for excluding older adults

Cumulative incidence of in-hospital mortality estimated to be 37.4 percent at 90 days

For all donors of convalescent plasma, drop seen in anti-RBD antibody levels from first to last donation